IP Library Granted Patent US 7,049,286
Granted Patent B2
US 7,049,286 · App. 10/231,894 · Granted May 23, 2006

Insulin conjugates and methods of use thereof

Assignee: Diatos, S.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,049,286
App. No.
10/231,894
Granted
May 23, 2006
Kind
B2
Abstract

The invention relates generally to chimeric peptides and compositions that facilitate the transport of insulin across biological membranes, methods for preparing the chimeric peptides, and a method for treating a subject suffering from diabetes.

Claims (15)

1. A chimeric peptide comprising a first domain and a second domain, wherein the first domain comprises the translocation sequence of SEQ ID NO:30 which facilitates active transport across a biological membrane and the second domain comprises at least a biologically active portion of an insulin polypeptide.

2. The peptide of claim 1 , wherein the translocation sequence binds an aminoglycan.

3. The peptide of claim 2 , wherein the aminoglycan is heparin or chondroitin sulfate.

4. The peptide of claim 1 , wherein the chimeric protein translocates a physiological barrier.

5. The peptide of claim 4 , wherein physiological barrier is the gastrointestinal barrier or the blood-brain barrier.

6. The peptide of claim 1 , further comprising a third domain selected from the group consisting of:

(a) a CDR3 region of a human anti-DNA antibody;

(b) a CDR2 region of a human anti-DNA antibody;

(c) a CDR3 region of a murine anti-DNA antibody; and

(d) a CDR2 region of a murine anti-DNA antibody.

7. A composition comprising a peptide according to claim 1 or 6 and a pharmaceutically acceptable diluent, carrier or adjuvant.

8. The composition according to claim 7 in a formulation suitable for oral administration.

9. A kit comprising in one or more containers, the composition of claim 7 .

10. The chimeric peptide of claim 1 , wherein the second domain comprising at least a biologically active portion of an insulin polypeptide still has at least one function of native insulin.

11. The chimeric peptide of claim 10 , wherein the at least one function of native insulin is decreasing blood glucose levels.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2003
From: TCHELINGERIAN, JEAN-LEON
To: DIATOS SA
Reel/Frame 013945/0285 →
Continuity (2)
Provisional Application 6031606300 · Aug 30, 2001
Related Publication 20030153490A1 · Aug 14, 2003